&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-12-04, 14:05

Biggest Office Party Night of the Year Set for Unprecedented Surge in 0.0 Drinking
Melvina Mahler

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-11-08, 18:15

Ecorobotix Showcases World-First AI Capability for Safe, Targeted Use of Non-Selective Contact Herbicides at Agritechnica

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-01, 14:05

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-08-09, 02:25

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-04-28, 20:23

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-02-19, 19:05

Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Lesley Moroney

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-22, 19:00

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
Kaitlyn Granata

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-09, 22:45

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-08-27, 14:05

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Britney MacDevitt

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-26, 19:10

A21 Launches Host Applications for Walk for Freedom 2024
Bradley Crotty

Popular Posts